Nuclear imaging of autoimmunity: Focus on IBD and RA

Autoimmunity

Volumn 43, Issue 7, 2010, Pages 539-549

  McBride, Helen J ^a  

^a AMGEN INC   (United States)

Author keywords

IBD; Imaging; man; mouse; RA

Indexed keywords

COPPER 64; FLUORODEOXYGLUCOSE F 18; IODINE 123; LIPOCORTIN 5; TECHNETIUM 99M;

AUTOIMMUNITY; BONE METABOLISM; CELL MIGRATION; ENTERITIS; HUMAN; IMAGING SYSTEM; INFLAMMATION; MOLECULAR IMAGING; MOLECULAR THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TARGET ORGAN;

ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; DIAGNOSTIC IMAGING; HUMANS; INFLAMMATORY BOWEL DISEASES; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77957980588     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916931003674766     Document Type: Review

References (70)

1. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009;70(3):382-392.
2. Thakur ML. Genomic biomarkers for molecular imaging: Predicting the future. Semin Nucl Med 2009;39(4):236-246.
3. Phelps ME. PET: Molecular imaging and its biological applications. New York: Springer; 2004. p 624.
4. Vallabhajosula S. Molecular imaging: Radiopharmaceuticals for PET and SPECT. New York: Springer; 2009. p 372.
5. Israel O, Goldsmith SJ. Hybrid SPECT/CT Imaging in clinical practice. New York: Informa Healthcare; 2006. p 264.
6. Kerry JE, Marshall C, Griffiths PA, James MW, Scott BB. Comparison between Tc-HMPAO labelled white cells and Tc leukoscan in the investigation of inflammatory bowel disease. Nucl Med Commun 2005;26(3):245-251.
7. Papos M, Nagy F, Narai G, Rajtar M, Szantai G, Lang J, Csernay L. Anti-granulocyte immunoscintigraphy and [99mTc] hexamethylpropyleneamine-oxime- labeled leukocyte scintigraphy in inflammatory bowel disease. Dig Dis Sci 1996; 41(2):412-420.
8. Stokkel MP, Reigman HE, Pauwels EK. Scintigraphic head-to-head comparison between 99mTc-WBCs and 99mTc-leukoscan in the evaluation of inflammatory bowel disease: A pilot study. Eur J Nucl Med Mol Imag 2002;29(2): 251-254.
9. Koutroubakis IE, Koukouraki SI, Dimoulios PD, Velidaki AA, Karkavitsas NS, Kouroumalis EA. Active inflammatory bowel disease: Evaluation with 99mTc (V) DMSA scintigraphy. Radiology 2003;229(1):70-74.
10. Lee B-F, Chiu N-T, Wu D-C, Tsai K-B, Liu G-C, Yu H-S, Wang S-T. Use of 99mTc (V) DMSA scintigraphy in the detection and localization of intestinal inflammation: Comparison of findings at colonoscopy and biopsy. Radiology 2001;220(2):381-385.
11. Stathaki MI, Koutroubakis IE, Koukouraki SI, Karmiris KP, Moschandreas JA, Kouroumalis EA, Karkavitsas NS. Active inflammatory bowel disease: Head-to-head comparison between 99mTc-hexamethylpropylene amine oxime white blood cells and 99mTc(V)-dimercaptosuccinic acid scintigra-phy. Nucl Med Commun 2008;29(1):27-32.
12. Vucelic B. Inflammatory bowel diseases: Controversies in the use of diagnostic procedures. Dig Dis 2009;27(3):269-277.
13. Biancone L, Schillaci O, Capoccetti F, Bozzi RM, Fina D, Petruzziello C, Geremia A, Simonetti G, Pallone F. Technetium 2 99m-HMPAO labeled leukocyte single photon emission computerized tomography (SPECT) for assessing Crohn's disease extent and intestinal infiltration. Am J Gastroenterol 2005;100(2):344-354.
14. Weldon MJ, Masoomi AM, Britten AJ, Gane J, Finlayson CJ, Joseph AE, Maxwell JD. Quantification of inflammatory bowel disease activity using technetium 299m HMPAO labelled leucocyte single photon emission computerised tomography (SPECT). Gut 1995;36(2):243-250.
15. Charron M, DiLorenzo C, Kocoshis S. CTand 99mTc-WBC vs colonoscopy in the evaluation of inflammation and complications of inflammatory bowel diseases. J Gastroenterol 2002;37(1):23-28.
16. Kolkman JJ, Falke TH, Roos JC, Van Dijk DH, Bannink IM, Den Hollander W, Cuesta MA, Peña AS, Meuwissen SG. Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findings. Dig Dis Sci 1996;41(4):641-650.
17. Molnar T, Papos M, Gyulai C, Ambrus E, Kardos L, Nagy F, Palko A, Pavics L, Lonovics J. Clinical value of technetium 2 99m-HMPAO-labeled leukocyte scintigraphy and spiral computed tomography in active Crohn's disease. Am J Gastroenterol 2001;96(5):1517-1521.
18. Charron M, del Rosario FJ, Kocoshis SA. Pediatric inflammatory bowel disease: Assessment with scintigraphy with 99mTc white blood cells. Radiology 1999;212(2): 507-513.
19. Charron M, Di Lorenzo C, Kocoshis S. Are 99mTc leukocyte scintigraphy and SBFT studies useful in children suspected of having inflammatory bowel disease? Am J Gastroenterol 2000; 95(5):1208-1212.
20. Sciarretta G, Furno A, Mazzoni M, Basile C, Malaguti P. Technetium 2 99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: Diagnostic and clinical relevance. Gut 1993;34(10):1364-1369.
21. Bennink RJ, Peeters M, Rutgeerts P, Mortelmans L. Evaluation of early treatment response and predicting the need for colectomy in active ulcerative colitis with 99mTc-HMPAO white blood cell scintigraphy. J Nucl Med 2004;45(10):1698-1704.
22. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol 2009;10(8):816-824.
23. Hijazi Y, Welker H, Dorr AE, Tang J-P, Blain R, Renzetti LM, Abbas R. Pharmacokinetics, safety, and tolerability of R411, a dual a4b1-a4b7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J Clin Pharmacol 2004;44(12):136-178.
24. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. N Engl J Med 2005;352(24):2499-2507.
25. 123-Inter-leukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000;41(2):242-249.
26. Gratz S, Rennen HJJM, Boerman OC, Oyen WJG, Corstens FHM. Rapid imaging of experimental colitis with 99mTc-interleukin-8 in rabbits. J Nucl Med 2001;42(6): 917-923.
27. Van den Brande JMH, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJW, van Deventer SJH, Peppelenbosch MP, Hommes DW. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007;56(4): 509-517.
28. MitomaH,HoriuchiT,HattaN,TsukamotoH,HarashimaS-I, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[alpha]. Gastroenterology 2005;128(2):376-392.
29. Van den Brande JMH, Braat H, Van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJH. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124(7):1774-1785.
30. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastro-enterology 2001;121(5):1088-1094.
31. Lemberg DA, Issenman RM, Cawdron R, Green T, Mernagh J, Skehan SJ, Nahmias C, Jacobson K. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflam Bowel Dis 2005;11(8): 733-738.
32. Loffler M, Weckesser M, Franzius C,Schober O, Zimmer K-P. High diagnostic value of 18FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann NY Acad Sci 2006;1072:379-385.
33. Neurath MF, Vehling D, Schunk K, Holtmann M, Brockmann H, Helisch A, Orth T, Schreckenberger M, Galle PR, Bartenstein P. Non-invasive assessment of Crohn's disease activity: A comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 2002;97(8):1978-1985.
34. Meisner RS, Spier BJ, EinarssonS,Roberson EN, Perlman SB, Bianco JA, Taylor AJ, Einstein M, Jaskowiak CJ, Massoth KM, et al. Pilot study using PET/CT as a novel, non-invasive assessment of disease activity in inflammatory bowel disease. Inflam Bowel Dis 2007;13(8):993-1000.
35. Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R. Non-invasive assessment of Crohn's disease intestinal lesions with 18F-FDG PET/CT.J Nucl Med 2007;48(7):1053-1059.
36. Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M. PET/ CT in the evaluation of inflammatory bowel disease: Studies in patients before and after treatment. Mol Imaging Biol 2010; 12:85-88.
37. Rubin DT, Surma BL, Gavzy SJ, Schnell KM, Bunnag AP, Huo D, Appelbaum DE. Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflam Bowel Dis 2009;15(5):750-755.
38. Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B 1992;19(2):183-190.
39. Forstrom LA, Dunn WL, Mullan BP, Hung JC, Lowe VJ, Thorson LM. Biodistribution and dosimetry of [(18)F]fluor-odeoxyglucose labelled leukocytes in normal human subjects. Nucl Med Commun 2002;23(8):721-725.
40. Pio BS, Byrne FR, Aranda R, Boulay G, Spicher K, Song MH, Birnbaumer L, Phelps ME, Czernin J, Silverman DHS. Non-invasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells. Mol Imag Biol 2003;5(4):271-277.
41. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, Phelps ME, Witte ON. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2[prime]-deoxycytidine analog. Nat Med 2008;14(7):783-788.
42. Locke LW, Chordia MD, Zhang Y, Kundu B, Kennedy D, Landseadel J, Xiao L, Fairchild KD, Berr SS, Linden J, et al. A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64Cu. J Nucl Med 2009;50(5):790-797.
43. Petra J, Maurits WVT, Henriette EVDH, Jasper F, Chris JM, Daniëlle AW. Inflammatory bowel disease: A systematic review on the value of diagnostic testing in primary care. Colorectal Dis 2009 Nov 13. [Epub ahead of print]
44. Liberatore M, Clemente M, Lurilli AP, Zorzin L, Marini M, Di Rocco E, Colella AC. Scintigraphic evaluation of disease activity in rheumatoid arthritis: A comparison of technetium 299m human non-specific immunoglobulins, leucocytes and albumin nanocolloids. Eur J Nucl Med 1992;19:853-857.
45. Breedveld FC, van Kroonenburgh MJPG, Camps JAJ, Feitsma HIJ, Markusse HM, Pauwels EKJ. Imaging of inflammatory arthritis with technetium 2 99m-labeled IgG. J Nucl Med 2017;30(12)-21.
46. Palosaari K, Vuotila J, Takalo R, Jartti A, Niemela R, Haapea M, Soini I, Tervonen O, Hakala M. Contrast-enhanced dynamic and static MRI correlates with quantitative 99Tcm-labelled nanocolloid scintigraphy. Study of early rheumatoid arthritis patients. Rheumatology 2004;43(11): 1364-1373.
47. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheum 2005;1(1): 47-54.
48. Ostendorf B, Scherer A, Wirrwar A, Hoppin JW, Lackas C, Schramm NU, Cohnen M, Mödder U, Berg WBvd, Müller HW, et al. High-resolution multipinhole single-photon-emission computed tomography in experimental and human arthritis. Arthritis Rheum 2006;54(4):1096-1104.
49. Ostendorf B, Mattes-György K, Reichelt DC, Blondin D, Wirrwar A, LanzmanR,Müller HW, SchneiderM,Mödder U, Scherer A. Early detection of bony alterations in rheumatoid and erosive arthritis of finger joints with high-resolution single photon emission computed tomography, and differentiation between them. Skeletal Radiol 2010;39(1):55-61.
50. Barrera P, van der Laken CJ, Boerman OC, Oyen WJG, van de Ven MTP, van Lent PLEM, van de Putte LBA, Corstens FHM. Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology 2000;39(8):870-874.
51. Barrera P, Oyen WJG, Boerman OC, van Riel PLCM. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62(9): 825-828.
52. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Meth 2009;348(1-2):36-41.
53. Zinn KR, Chaudhuri TR, Smyth CA, Wu Q, Liu H-G, Fleck M, Mountz JD, Mountz JM. Specific targeting of activated endothelium in rat adjuvant arthritis with a 99mTc-radiolabeled E-selectin-binding peptide. Arthritis Rheum 1999;42(4):641-649.
54. Jones HA, Cadwallader KA, White JF, Uddin M, Peters AM, Chilvers ER. Dissociation between respiratory burst activity and deoxyglucose uptake in human neutrophil granulocytes: Implications for interpretation of 18F-FDG PET images. J Nucl Med 2002;43(5):652-657.
55. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeox-yglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33(11):1972-1980.
56. Paik J-Y, Lee K-H, Choe YS, Choi Y, Kim B-T. Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med 2004;45(1):124-128.
57. Polisson RP, Schoenberg OI, FischmanA, RubinR,Simon LS, Rosenthal D, Palmer WE. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 1995;38(6):819-825.
58. Palmer WE, Rosenthal DI, Schoenberg OI, Fischman AJ, Simon LS, Rubin RH, Polisson RP. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;196(3):647-655.
59. Beckers C, Jeukens X, Ribbens C, André B, Marcelis S, Leclercq P, Kaiser MJ, Foidart J, Hustinx R, Malaise MG. (18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloprotei-nase-3. Eur J Nucl Med Mol Imag 2006;33(3):275-280.
60. Ju JH, Kang KY, Kim IJ, Yoon JU, Kim HS, Park SH, Kim HY. Visualization and localizationofrheumatoid knee synovitis with FDG-PET/CT images. Clin Rheumatol 2008;27(Suppl 2): S39-S41.
61. Vogel WV, van Riel PLCM, Oyen WJ. FDG-PET/CT can visualise the extent of inflammation in rheumatoid arthritis of the tarsus. Eur J Nucl Med Mol Imag 2007;34:349.
62. Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Möttönen T, Nuutila P, Minn H. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003;48(11):3077-3084.
63. Van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CFM, van der Heijden JW, Maruyama K, Boellaard R, Dijkmans BAC, Lammertsma AA, Voskuyl AE. Non-invasive imaging of macrophages in rheumatoid synovitis using C11-PK11195 and positron emission tomography. Arthritis Rheum 2008;58(11):3350-3355.
64. Maarten CK, Hans V, Margreet J, Barry B, Wendy JP, Bert ATH, Ferdinand CB, Paul PT. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998; 41(8):1481-1488.
65. Chauveau F, VanCamp N, Dolle F, Kuhnast B, Hinnen F, Damont A, Boutin H, James M, Kassiou M, Tavitian B. Comparative evaluationofthe translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med 2009;50(3): 468-476.
66. Fujimura Y, Zoghbi SS, Simeon FG, Taku A, Pike VW, Innis RB, Fujita M. Quantification of translocator protein (18kDa) in the human brain with PET and a novel radioligand, 18F-PBR06. J Nucl Med 2009;50(7): 1047-1053.
67. Wagner S, Breyholz HJ, Faust A, Höltke C, Levkau B, Schober O, Schäfers M, Kopka K. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr Med Chem 2006;13: 2819-2838.
68. Hammond LA, Denis L, Salman U, Jerabek P, Thomas CRJ, Kuhn JG. Positron emission tomography (PET): Expanding the horizons of oncology drug development. Invest New Drugs 2003;21(3):309-340.
69. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 2008; 14(28):2983-2998.
70. Rottey S, Signore A, Van de Wiele C. Radiolabelled chemotherapeutics. Q J Nucl Med Mol Imag 2007;51(2): 139-151.